Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Bioenvision seeks clearance for phase I studies of clofarabine in psoriasis

Nov. 14, 2006

Peptimmune and Orphan Europe partner to develop drug for pemphigus vulgaris

Nov. 14, 2006

Phase IIb study evaluates AN-0128 in children with atopic dermatitis

Nov. 13, 2006

Recent Dabur patent describes novel peptide-based therapeutic agents for alopecia

Nov. 8, 2006

TopoTarget licenses preclinical HDAC inhibitor to LEO Pharma

Nov. 6, 2006

Fluphenazine decanoate to be evaluated for the management of psoriasis in phase II clinical trial

Oct. 31, 2006

Novel tyrosinase inhibitors for skin hyperpigmentation claimed by Galderma

Oct. 30, 2006

Promising preliminary results for ASF-1096 formulation in cutaneous lupus erythematosus

Oct. 26, 2006

ASF-1057 begins phase IIb studies for seborrheic dermatitis

Oct. 26, 2006

Desonate approved for mild to moderate atopic dermatitis

Oct. 24, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...